

Calvert Small Mid-Cap Fund

Key Takeaways

- Small/mid-cap U.S. stocks delivered strong outperformance versus large caps in the first quarter of 2026, with the Russell 2500 Index (the Index) outperforming the S&P 500 Index by 6.7%.
- Energy was the clear leader in the Index, rising 38.2% on geopolitical and macroeconomic events.
- Calvert Small Mid-Cap Fund (the Fund) trailed its benchmark, the Russell 2500 Index, during the quarter.
- The Fund's underweights to energy and to more speculative and lower quality stocks were the primary headwinds during the period.
- The underweight to energy is an outcome of Calvert's disciplined, bottom-up process that may result in lower exposure to traditional fossil-fuel oriented businesses, particularly where long-term capital discipline, governance or transition readiness may not align with the Calvert Principles for Responsible Investment.

Performance Review

In the quarter period ending March 31, 2026, the Portfolio's 1 shares returned -2.54% (net of fees)¹, while the benchmark returned 2.04%

During the quarter the market rewarded speed over stability, as a momentum-led rally favored more speculative, lower quality small/mid-cap names that are highly sensitive to shifts in economic expectations. In that environment, Calvert Small Mid-Cap Fund's quality bias — with its focus on durable business models, consistent profitability, and deliberate risk management — was less in demand. The Fund trailed the Russell 2500 Index for the first quarter, with the gap driven primarily by security selection and secondarily by sector allocation.

Two positioning features led the detractors from relative performance: an overweight in industrials, where company-specific results disappointed, and a pronounced underweight in energy, where the benchmark's strength translated into a meaningful opportunity cost. Within that broader backdrop, a few areas diversified² the return stream and added value through stock selection. Financials was the most helpful sector on a relative basis, led by financial services, where holdings and positioning avoided several benchmark laggards, though some of that benefit was offset by weaker results in banks and insurance. Real estate also added to relative performance, supported by an underweight exposure to weaker benchmark constituents, particularly in real estate management and development. Utilities rounded out the top contributors, delivering strong absolute gains within the portfolio and helping cushion the quarter's more cyclical and growth-sensitive exposures.

The main headwinds came from three sources. First, industrials was the largest drag: the portfolio's sizable exposure amplified the impact of weak stock selection, with capital goods the most consequential area alongside additional pressure from commercial and professional services and transportation. Second, energy detracted not because of stock picking, but because of what the portfolio did not own. With only a small allocation to energy, the Fund was unable to capitalize on the sector's sharp rally during the period. Third, information technology weighed on results, as technology hardware and equipment declined, only partly offset by strength in semiconductors and semiconductor equipment as well as pockets of resilience in software and services.

Looking back, the first quarter of 2026 was a period where market leadership and portfolio positioning briefly moved in opposite directions. Even as select holdings such as Diodes Inc. and Royalty Pharma plc contributed positively and defensive offsets in financials, real estate and utilities helped, the combination of weaker selection within large active bets (especially industrials) and an underweight in the quarter's strongest area (energy) drove the relative shortfall. Positioning over the quarter adds an important lens: weights were more clearly defined and, in places, more concentrated by quarter-end, including a relatively larger exposure in financials (and insurance) and meaningful sizing in parts of technology — areas that experienced negative returns during the period.

For investors, the takeaway is less about any individual sector call and more about the portfolio's intentional profile: a quality-oriented strategy can lag in momentum-led markets, but it also creates the opportunity to compound over full cycles when fundamentals reassert themselves. In our view, maintaining sizing discipline and monitoring concentration — particularly where active risk is largest — remains central to translating differentiated positioning into long-term excess returns.

¹ Source: Calvert. Data as of March 31, 2026. Performance for other share classes will vary.

² Diversification neither assures a profit nor guarantees against loss in a declining market.

This document constitutes a commentary and does not constitute investment advice nor a recommendation to invest. The value of investments may rise as well as fall. Independent investment advice should be sought before any decision to invest.

Contributors

- Diodes Incorporated manufactures semiconductor chips used in automotive, data centers, and a range of industrial applications. Following a multiyear cyclical downturn, the company returned to impressive growth — among the highest rates in its peer group — with first quarter 2026 guidance implying an acceleration. The company is strengthening its competitive position through innovation, including the launch of new, higher margin products in the auto and industrial end markets that are contributing to share gains. Against this backdrop, we believe the market is materially undervaluing the company's earnings power.
- Royalty Pharma is a leading acquirer of biopharmaceutical royalties and revenue interests, offering diversified exposure to a portfolio of marketed therapies and development-stage assets. The holding contributed positively during the quarter, as investor confidence improved around the durability of portfolio cash flows and the company's ability to deploy capital into new royalty investments at attractive returns, supporting expectations for compounding value over time. In a market that frequently rotated between high-beta momentum and more defensive exposures, Royalty Pharma's cash-generative model and comparatively lower fundamental volatility helped support absolute performance and added diversification² within the health care sleeve of the portfolio.

Detractors

- CBIZ, Inc. is a leading national provider of professional services to middle-market businesses, focusing on accounting, tax, advisory, benefits, insurance and technology solutions. We sold CBIZ during the quarter on concerns around its risk-reward profile. The company's recent acquisition of Marcum has not been seamless and has weighed on the stock. We believe there are better opportunities within the sector. CBIZ, along with most other professional services names, also sold off on fears that artificial intelligence (AI) will cause significant disruption to its business.
- CSW Industrials is a U.S.-based industrial company that owns a portfolio of specialty products, with over 70% of sales coming from accessory products used in the installation of residential heating, ventilation, air conditioning (HVAC) and refrigeration systems. The remainder of sales is split between highly specified building products and industrial maintenance solutions. The company detracted from performance during the quarter as shares pulled back following a modest sales decline that was driven by weakness in new residential HVAC installations. While we believe conditions have moved past the worst of the disruption and that growth should resume later in the year, near-term results and forward commentary pointed to softer demand and some margin pressure from input costs and operating leverage, which weighed on investor confidence in the pace of earnings growth.

Market Outlook

Markets are increasingly being driven by momentum and thematic narratives that are often disconnected from underlying fundamentals, while geopolitical uncertainty continues to weigh on sentiment despite a resilient economic backdrop. This dynamic is creating a widening gap between price and intrinsic value. In our view, long-term performance remains anchored in companies that generate durable earnings and consistent economic value. While this belief is often tested during periods dominated by sentiment and rapid shifts in market leadership, history suggests these dislocations are temporary. It is precisely in these environments that maintaining a focus on quality while selectively adapting to changing market conditions becomes most critical.

Rather than reacting to a rapidly shifting market environment, we have remained deliberate in our portfolio positioning. We have selectively increased exposure to high quality businesses where valuations have become more compelling, while exiting positions where our conviction and long-term earnings durability has weakened. Our objective is to capitalize on periods of market dislocation — when extremes in optimism and pessimism create opportunity to invest in companies with sustainable earnings power at attractive prices.

The current environment reinforces the importance of a disciplined and repeatable investment process. Our definition of quality — centered on businesses with durable competitive advantages, strong balance sheets and capable management teams — has not always been rewarded in the short term, but has proven resilient across market cycles, particularly during periods of dislocation. We remain focused on identifying opportunities where this disconnect between fundamentals and valuation is most pronounced and where we believe the market is underestimating the durability of long-term earnings power.

Our Quality, Valuation and Time (QVT) strategy focuses on identifying high quality, responsible companies with durable earnings, strong balance sheets and disciplined capital allocation that are trading at reasonable valuations. We believe these characteristics position businesses to compound value over time and participate meaningfully in up markets while demonstrating resilience during periods of stress.

² Diversification neither assures a profit nor guarantees against loss in a declining market.

Fund Facts

Class I inception	09/18/2023
Class A inception	09/18/2023
Performance inception	07/29/2011
Benchmark	Russell 2500 Index
Class I expense ratio	Gross 0.96 %
	Net 0.90 %
Class A expense ratio	Gross 1.21 %
	Net 1.15 %

Where the net expense ratio is lower than the gross expense ratio, certain fees have been waived and/or expenses reimbursed. These waivers and/or reimbursements will continue for at least one year from the date of the applicable fund's current prospectus (unless otherwise noted in the applicable prospectus) or until such time as the fund's Board of Trustees acts to discontinue all or a portion of such waivers and/or reimbursements. Absent such waivers and/or reimbursements, returns would have been lower. Expenses are based on the fund's current prospectus, in effect as of the date of this commentary. For information on the applicable fund's current fees and expenses, please see the fund's current prospectus. The minimum investment is \$1,000 for A Shares and \$1,000,000 for I Shares.

Performance (%)

As of March 31, 2026	MTD	QTD	YTD	1 YR	3 YR	5 YR	10 YR
Class I Shares at NAV	-6.81	-2.54	-2.54	-3.67	2.72	1.17	7.57
Class A Shares at NAV	-6.80	-2.54	-2.54	-3.86	2.47	0.93	7.31
A Shares with Max. 5.25% Sales Charge	-11.68	-7.67	-7.67	-8.91	0.64	-0.15	6.73
Russell 2500 Index	-5.13	2.04	2.04	23.45	13.25	5.48	10.58

Performance data quoted represents past performance, which is no guarantee of future results, and current performance may be lower or higher than the figures shown. For the Fund's performance as of the most recent month-end, please refer to calvert.com. Investment returns and principal value will fluctuate and fund shares, when redeemed, may be worth more or less than their original cost.

Returns are net of fees and assume the reinvestment of all dividends and income. Returns for less than one year are cumulative (not annualized). Performance of other share classes will vary.

Top 10 Holdings (% of Total Net Assets)^	FUND
CSW Industrials Inc	3.11
Burlington Stores Inc	2.66
Royalty Pharma PLC	2.37
Wyndham Hotels & Resorts Inc	2.34
Aramark	2.30
Franklin Electric Co Inc	2.27
Performance Food Group Co	2.27
Dorman Products Inc	2.23
Donaldson Co Inc	2.20
Valvoline Inc	2.03

^ Top 10 Holdings excludes cash and equivalents. Portfolio profile subject to change due to active management.

On September 15, 2025, the Calvert Mid-Cap Fund merged into the Calvert Small/Mid-Cap Fund. There were no changes to the investment team, philosophy, or policy of the Calvert Small/Mid-Cap Fund in conjunction with the merger.

INDEX INFORMATION

The **Russell 2500® Index** is an index that measures the small to mid-cap segment of the U.S. equity universe, commonly referred to as "smid" cap. It includes the smallest 2500 securities in the Russell 3000.

The **Standard & Poor's 500® Index** (S&P 500®) measures the performance of the large cap segment of the U.S. equities market, covering approximately 80% of the U.S. equities market. The Index includes 500 leading companies in leading industries of the U.S. economy.

The **Russell 2500® Growth Index** is an index that measures the performance of those Russell 2500 companies with higher price-to-book ratios and higher forecasted growth values.

The **Russell 2500® Value Index** is an index that measures the performance of the small to mid-cap value segment of the U.S. equity universe. It includes those Russell 2500 companies with lower price-to-book ratios and lower forecasted growth values.

The indexes are unmanaged and do not include any expenses, fees or sales charges. It is not possible to invest directly in an Index. Any index referred to herein is the intellectual property (including registered trademarks) of the applicable licensor. Any product based on the index is in no way sponsored, endorsed, sold or promoted by the applicable licensor and it shall not have any liability with respect thereto.

RISK CONSIDERATIONS: The value of investments held by the Fund may increase or decrease in response to economic, and financial events (whether real, expected or perceived) in the U.S. and global markets. The value of equity securities is sensitive to stock market volatility. Smaller companies are generally subject to greater price fluctuations, limited liquidity, higher transaction costs and higher investment risk than larger, more established companies. Investing primarily in responsible investments carries the risk that, under certain market conditions, the Fund may underperform funds that do not utilize a responsible investment strategy. The Fund is exposed to liquidity risk when trading volume, lack of a market maker or trading partner, large position size, market conditions, or legal restrictions impair its ability to sell particular investments or to sell them at advantageous market prices. The impact of the coronavirus on global markets could last for an extended period and could adversely affect the Fund's performance. No fund is a complete investment program and you may lose money investing in a fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description

IMPORTANT INFORMATION

The views and opinions and/or analysis expressed are those of the investment team as of the date of preparation of this

material and are subject to change at any time without notice due to market or economic conditions and may not necessarily come to pass. Furthermore, the views will not be updated or otherwise revised to reflect information that subsequently becomes available or circumstances existing, or changes occurring, after the date of publication. The views expressed do not reflect the opinions of all investment personnel at Morgan Stanley Investment Management (MSIM) and its subsidiaries and affiliates (collectively "the Firm"), and may not be reflected in all the strategies and products that the Firm offers.

This material is a general communication, which is not impartial and all information provided has been prepared solely for informational and educational purposes and does not constitute an offer or a recommendation to buy or sell any particular security or to adopt any specific investment strategy. The information herein has not been based on a consideration of any individual investor circumstances and is not investment advice, nor should it be construed in any way as tax, accounting, legal or regulatory advice. To that end, investors should seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision.

Certain information herein has been prepared on the basis of publicly available information, internally developed data and other third-party sources believed to be reliable. However, no assurances are provided regarding the reliability of such information and the Firm has not sought to independently verify information taken from public and third-party sources.

Please consider the investment objective, risks, charges and expenses of the fund carefully before investing. The prospectus contains this and other information about the fund. To obtain a prospectus (which includes the applicable fund's current fees and expenses, if different from those in effect as of the date of this commentary), download one at <https://funds.eatonvance.com/all-mutual-funds.php> or contact your financial professional. Please read the prospectus carefully before investing.

The whole or any part of this material may not be directly or indirectly reproduced, copied, modified, used to create a derivative work, performed, displayed, published, posted, licensed, framed, distributed or transmitted or any of its contents disclosed to third parties without MSIM's express written consent. This material may not be linked to unless such hyperlink is for personal and non-commercial use. All information contained herein is proprietary and is protected under copyright and other applicable law.

Eaton Vance and Calvert are part of Morgan Stanley Investment Management. Morgan Stanley Investment Management is the asset management division of Morgan Stanley.